Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19
Latest Information Update: 31 Jul 2023
At a glance
- Drugs Myelo 001 (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Sponsors Valenta Pharmaceuticals
Most Recent Events
- 25 Jul 2023 Status changed from recruiting to completed.
- 02 Feb 2022 New trial record